Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24058299 | 0.92 | POLB (0.57) | POLBALDH1A1CYP2D6HSD11B1MAPT | |
| SCHEMBL30885691 | 0.86 | POLB (0.58) | POLBALDH1A1CYP2D6MAPTSMN1; SMN2 | |
| SCHEMBL23779189 | 0.86 | POLB (0.58) | POLBALDH1A1CYP2D6MAPTSMN1; SMN2 | |
| SCHEMBL12751726 | 0.85 | POLB (0.68) | POLBALDH1A1CYP2D6LMNAHTT | |
| SCHEMBL24058319 | 0.82 | POLB (0.68) | POLBALDH1A1CYP2D6HSD11B1LMNA | |
| SCHEMBL1975333 | 0.81 | POLB (0.63) | POLBALDH1A1CYP2D6MAPTSMN1; SMN2 | |
| SCHEMBL24025547 | 0.80 | ALDH1A1 (0.56) | POLBALDH1A1CYP2D6MAPTSMN1; SMN2 | |
| SCHEMBL2977562 | 0.79 | POLB (0.97) | POLBALDH1A1CYP2D6MAPTSMN1; SMN2 | |
| SCHEMBL23089669 | 0.79 | POLB (0.90) | POLBALDH1A1CYP2D6MAPTLMNA | |
| SCHEMBL3203109 | 0.79 | POLB (0.72) | POLBALDH1A1CYP2D6SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873600-B9 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2024-02-14 | — | — | EP | disclosed |
| EP-3873599-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3873600-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-20 | — | — | EP | disclosed |
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| US-20210353608-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353608-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ARSA, SULT1A1, SULT2A1 | POLB 4024/4885ALDH1A1 455/4885CYP2D6 53/4885 |
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ARSA, SULT1A1, SULT2A1 | POLB 4024/4885ALDH1A1 455/4885CYP2D6 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.